Fate Therapeutics Inc. (FATE)
NASDAQ: FATE
· Real-Time Price · USD
1.60
0.26 (19.40%)
At close: Jun 06, 2025, 3:59 PM
1.63
1.56%
After-hours: Jun 06, 2025, 05:39 PM EDT
19.40% (1D)
| Bid | 1.52 |
| Market Cap | 183.99M |
| Revenue (ttm) | 13.34M |
| Net Income (ttm) | -175.88M |
| EPS (ttm) | -1.41 |
| PE Ratio (ttm) | -1.14 |
| Forward PE | -1.12 |
| Analyst | Hold |
| Ask | 1.69 |
| Volume | 4,537,781 |
| Avg. Volume (20D) | 1,919,220 |
| Open | 1.36 |
| Previous Close | 1.34 |
| Day's Range | 1.36 - 1.68 |
| 52-Week Range | 0.66 - 5.92 |
| Beta | 2.23 |
About FATE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FATE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FATE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+21.17%
Fate Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+2.64%
Fate Therapeutics shares are trading higher after the company unveiled its Phase 1 data for FT819 CAR T-cell therapy in systemic lupus erythematosus. Its first three patients showed rapid and sustained b-cell depletion with no dose-limiting toxicities.
1 month ago · seekingalpha.com
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy SectorI've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determ...
